CTRI/2024/06/068998尚未招募2 期
An Open label pilot clinical trial to evaluate the effectiveness of SoothagaMezhugu in the management of Soothaga Vaayu (Poly Cystic Ovarian Syndrome) - NI
il0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participants must meet the diagnostic criteria for Polycystic Ovary Syndrome (PCOS) as per Rotterdam criteria.
- •Women of reproductive age, typically between 18 to 35 years old, should be included.
- •Non-pregnant participants or those not actively seeking pregnancy should be included.
- •Participants must demonstrate willingness and ability to comply with study requirements, including attending study visits, adhering to treatment protocols, and providing informed consent.
排除标准
- •Pregnant women or those actively trying to conceive.
- •Women who have reached menopause or are in the perimenopausal period.
- •Hypothyroidism patients.
- •Participants with significant medical conditions (e.g., uncontrolled diabetes, cardiovascular disease, severe liver or kidney dysfunction).
- •Participants currently using hormonal medications such as oral contraceptives, hormonal replacement therapy, or anti-androgenic medications should be excluded.
- •Participants with a history of ovarian surgery.
- •Participants currently enrolled in other clinical trials.
- •Individuals lacking the capacity to provide informed consent.
研究者
相似试验
尚未招募
2 期
Clinical Trial for Diabetic Foot Ulcer through Siddha medicinesCTRI/2023/10/058661ational Institute of Siddha
已完成
1 期
A Clinical study on quadrivalent Human Papilloma virus vaccineCTRI/2017/02/007785Serum Institute of India Pvt Ltd47
已完成
1 期
A clinical study to assess safety and tolerability of tetanus, diptheria, and pertussis vaccine in adults.CTRI/2017/03/008003Serum Institute of India Pvt Ltd23
尚未招募
2 期
Assesment safety and efficacy of Ayurvedic Formulation AYUSH AGT in external wounds.CTRI/2020/04/024658Central council for Research in Ayurvedic Sciences
已完成
1 期
Phase I clinical trial to evaluate the safety,tolerance and immune response ofChikungunya vaccine in healthy adults of 18 to 50 years ageCTRI/2020/04/024533Bharat Biotech International limited20
